Published in Infect Immun on January 01, 1980
The dengue viruses. Clin Microbiol Rev (1990) 4.72
In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B, and NS3. J Virol (1990) 3.50
Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Health Organ (1987) 1.57
Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice. J Virol (2001) 1.33
Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J Virol (2002) 1.32
Dengue virus-induced hemorrhage in a nonhuman primate model. Blood (2009) 1.29
Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun (1981) 1.28
Dengue-2 vaccine: viremia and immune responses in rhesus monkeys. Infect Immun (1980) 1.27
A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice. J Virol (2006) 0.99
Antibody response to dengue-2 vaccine measured by two different radioimmunoassay methods. J Clin Microbiol (1984) 0.97
Monoclonal antibodies specific for dengue virus type 3. J Clin Microbiol (1980) 0.92
In vitro virulence marker: growth of dengue-2 virus in human leukocyte suspension cultures. Infect Immun (1981) 0.86
Lack of greater seroconversion of rhesus monkeys after subcutaneous inoculation of dengue type 2 live-virus vaccine combined with infection-enhancing antibodies. Infect Immun (1981) 0.85
Temperature-sensitive events during the replication of the attenuated S-1 clone of dengue type 2 virus. Infect Immun (1983) 0.80
Sequence of the dengue virus type 2 (strain PR-159) NS1 gene and comparison with its vaccine derivative. Nucleic Acids Res (1993) 0.75
Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med (1977) 7.01
PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE. Science (1945) 4.05
Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infect Immun (1976) 2.67
Pandemic dengue in Caribbean countries and the southern United States--past, present and potential problems. N Engl J Med (1971) 1.98
Experimental studies on dengue. I. Isolation, identification and modification of the virus. J Infect Dis (1952) 1.93
Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates. Infect Immun (1977) 1.51
Effect of passage history on dengue-2 virus replication in subpopulations of human leukocytes. Infect Immun (1979) 1.44
Dengue-2 vaccine: viremia and immune responses in rhesus monkeys. Infect Immun (1980) 1.27
Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol (1956) 1.25
STUDIES ON JAPANESE B ENCEPHALITIS VIRUS VACCINES FROM TISSUE CULTURE. IV. PREPARATION AND CHARACTERIZATION OF POOL OF ATTENUATED OCT-541 LINE FOR HUMAN VACCINE TRIAL. J Immunol (1963) 1.14
Chemically induced temperature-sensitive mutants of dengue virus type 2: comparison of temperature sensitivity in vitro with infectivity suckling mice, hamsters, and rhesus monkeys. Infect Immun (1976) 1.09
Two variants of tick-borne encephalitis virus showing different plaque morphology. Virology (1963) 1.05
Development of a diploid cell line from fetal rhesus monkey lung for virus vaccine production. In Vitro (1973) 1.03
The highly attenuated E5"14" plaque-cloned derivative from the Langat TP21 E5 strain. Isolation and properties. Acta Virol (1973) 0.90
Demonstration of infectious DNA in transformed cells. II. Characterization of uptake of SV40-transformed mouse cell DNA by simian cells. Arch Virol (1975) 0.89
A spontaneous temperature sensitive mutant of Japanese encephalitis virus: preliminary characterization. Arch Virol (1977) 0.88
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 8.45
Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96
Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06
A plaque reduction test for dengue virus neutralizing antibodies. J Immunol (1967) 5.78
Flaviviridae. Intervirology (1985) 3.06
Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. Infect Immun (1976) 2.67
The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med (1973) 2.64
Detection of additional antigenic determinants of hepatitis B antigen. J Immunol (1972) 2.57
Bunyaviridae. Intervirology (1980) 2.53
Dengue virus identification by the plaque reduction neutralization test. J Immunol (1967) 2.45
Antigenic characterization of two sindbis envelope glycoproteins separated by isoelectric focusing. Virology (1976) 2.32
Detection of West Nile virus by the polymerase chain reaction and analysis of nucleotide sequence variation. Am J Trop Med Hyg (1993) 2.07
Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg (1987) 2.07
Togaviridae. Intervirology (1985) 1.96
Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis (1971) 1.95
Hemorrhagic fever in Thailand; recent knowledge regarding etiology. Jpn J Med Sci Biol (1967) 1.94
Swine influenza A at Fort Dix, New Jersey (January-February 1976). IV. Summary and speculation. J Infect Dis (1977) 1.88
Interaction of Sindbis virus with liposomal model membranes. J Virol (1975) 1.85
Dengue-virus recovery by direct and delayed plaques in LLC-MK2 cells. Am J Trop Med Hyg (1968) 1.80
Replication of dengue-2 virus in cultured human lymphoblastoid cells and subpopulations of human peripheral leukocytes. J Immunol (1976) 1.79
Radioimmune precipitation of group A arboviruses. J Immunol (1972) 1.71
Immunoprecipitation analysis of soluble complement-fixing antigens of dengue viruses. J Immunol (1970) 1.69
Change involving a viral membrane glycoprotein during morphogenesis of group B arboviruses. Virology (1972) 1.69
Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants. Infect Immun (1982) 1.69
An insular outbreak of dengue hemorrhagic fever. II. Virologic and serologic studies. Am J Trop Med Hyg (1968) 1.68
Immunological and biophysical separation of dengue-2 antigens. J Virol (1971) 1.66
Anti-dengue immunoglobulins and serum beta 1 c-a globulin levels in dengue shock syndrome. J Immunol (1969) 1.64
The proteins of Japanese encephalitis virus. Virology (1971) 1.63
An analysis of fevers of unknown origin in American soldiers in Vietnam. Ann Intern Med (1967) 1.61
Evidence for two mechanisms of dengue virus infection of adherent human monocytes: trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors. Infect Immun (1981) 1.58
Bunyaviruses and Bunyaviridae. Intervirology (1976) 1.58
Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg (1989) 1.57
Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella. J Immunol (1980) 1.56
Virulence and immunogenicity of a temperature-sensitive dengue-2 virus in lower primates. Infect Immun (1977) 1.51
Antibody response in dengue and dengue hemorrhagic fever. Jpn J Med Sci Biol (1967) 1.47
Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis (1996) 1.45
MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol (1999) 1.44
Effect of passage history on dengue-2 virus replication in subpopulations of human leukocytes. Infect Immun (1979) 1.44
Experimental infection of chimpanzees with dengue viruses. Am J Trop Med Hyg (1978) 1.39
Swine influenza A at Fort Dix, New Jersey (January-February 1976). I. Case finding and clinical study of cases. J Infect Dis (1977) 1.39
Swine influenza A at Fort Dix, New Jersey (January-February 1976). III. Extent of spread and duration of the outbreak. J Infect Dis (1977) 1.38
Partial purification and characterization of a dengue virus soluble complement-fixing antigen. J Immunol (1970) 1.37
Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis (1988) 1.37
Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol (1971) 1.36
Production and evaluation of a formalin-killed Chikungunya vaccine. J Immunol (1971) 1.35
Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect Immun (1991) 1.34
Sequential dengue virus infections in the white-handed gibbon (Hylobates lar). Am J Trop Med Hyg (1970) 1.33
Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis (1971) 1.33
Antigenic components of group A arbovirus virions. J Virol (1973) 1.30
Dengue virions and antigens in brain and serum of infected mice. J Virol (1970) 1.30
Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. J Virol (1988) 1.29
Human immunoglobulin specificity after group B arbovirus infections. Infect Immun (1972) 1.29
Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes. Arch Virol (1989) 1.29
Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun (1981) 1.28
Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis (1983) 1.27
Dengue-2 vaccine: viremia and immune responses in rhesus monkeys. Infect Immun (1980) 1.27
Cytological localization of Dengue-2 antigens: an immunological study with ultrastructural correlation. Infect Immun (1973) 1.26
Recovery of dengue viruses from patients during epidemics in Puerto Rico and East Pakistan. Am J Trop Med Hyg (1966) 1.25
RNA fingerprinting as a method for distinguishing dengue 1 virus strains. Am J Trop Med Hyg (1983) 1.25
Togaviridae. Intervirology (1978) 1.24
Comparison of dengue-2 and dengue-3 virus strains by neutralization tests and identification of a subtype of dengue-3. Am J Trop Med Hyg (1972) 1.23
Assay of arbovirus neutralizing antibody by micro methods. Trans R Soc Trop Med Hyg (1969) 1.21
Enteric immunization with live adenovirus type 21 vaccine. II. Systemic and local immune responses following immunization. Infect Immun (1972) 1.21
Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis (1984) 1.20
A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans. J Infect Dis (1994) 1.19
Enteritis and gastritis in young asymptomatic Pakistani men. Am J Dig Dis (1966) 1.19
Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am J Trop Med Hyg (1967) 1.19
Swine influenza A at Fort Dix, New Jersey (January-February 1976). II. Transmission and morbidity in units with cases. J Infect Dis (1977) 1.17
Detection of dengue cell-surface antigens by peroxidase-labeled antibodies and immune cytolysis. Infect Immun (1974) 1.16
A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine (2011) 1.15
Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg (1987) 1.13
The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women. J Clin Endocrinol Metab (2000) 1.12
Chikungunya virus vaccine prepared by Tween-ether extraction. Appl Microbiol (1970) 1.12
Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg (1984) 1.11